Nanjing Hicin Pharmaceutical Co Ltd (300584) - Total Liabilities
Based on the latest financial reports, Nanjing Hicin Pharmaceutical Co Ltd (300584) has total liabilities worth CN¥395.57 Million CNY (≈ $57.88 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 300584 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Nanjing Hicin Pharmaceutical Co Ltd - Total Liabilities Trend (2012–2025)
This chart illustrates how Nanjing Hicin Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Nanjing Hicin Pharmaceutical Co Ltd's assets to evaluate the company's liquid asset resilience ratio.
Nanjing Hicin Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Nanjing Hicin Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Sinotec Co Ltd
SHG:603121
|
China | CN¥953.01 Million |
|
Shandong Molong Petroleum Machinery Co Ltd
SHE:002490
|
China | CN¥2.03 Billion |
|
Cytek Biosciences Inc
NASDAQ:CTKB
|
USA | $121.47 Million |
|
SEC Electric Mach Co Ltd
SHG:603988
|
China | CN¥435.32 Million |
|
Tera Yatirim Menkul Degerler A.S.
IS:TERA
|
Turkey | TL1.80 Billion |
|
Mystate Ltd
AU:MYS
|
Australia | AU$14.61 Billion |
|
Chong Kun Dang Pharmaceutical
KO:185750
|
Korea | ₩803.02 Billion |
|
Hartadinata Abadi Tbk PT
JK:HRTA
|
Indonesia | Rp7.60 Trillion |
Liability Composition Analysis (2012–2025)
This chart breaks down Nanjing Hicin Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 300584 current and non-current assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nanjing Hicin Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nanjing Hicin Pharmaceutical Co Ltd (2012–2025)
The table below shows the annual total liabilities of Nanjing Hicin Pharmaceutical Co Ltd from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥432.26 Million ≈ $63.25 Million |
+1.38% |
| 2024-12-31 | CN¥426.37 Million ≈ $62.39 Million |
+1.19% |
| 2023-12-31 | CN¥421.37 Million ≈ $61.66 Million |
+22.71% |
| 2022-12-31 | CN¥343.38 Million ≈ $50.25 Million |
-2.87% |
| 2021-12-31 | CN¥353.53 Million ≈ $51.73 Million |
+55.37% |
| 2020-12-31 | CN¥227.55 Million ≈ $33.30 Million |
+5.74% |
| 2019-12-31 | CN¥215.19 Million ≈ $31.49 Million |
+0.91% |
| 2018-12-31 | CN¥213.26 Million ≈ $31.21 Million |
+86.07% |
| 2017-12-31 | CN¥114.61 Million ≈ $16.77 Million |
+21.08% |
| 2016-12-31 | CN¥94.66 Million ≈ $13.85 Million |
+8.12% |
| 2015-12-31 | CN¥87.55 Million ≈ $12.81 Million |
-6.50% |
| 2014-12-31 | CN¥93.63 Million ≈ $13.70 Million |
+24.04% |
| 2013-12-31 | CN¥75.49 Million ≈ $11.05 Million |
+30.09% |
| 2012-12-31 | CN¥58.03 Million ≈ $8.49 Million |
-- |
About Nanjing Hicin Pharmaceutical Co Ltd
Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company's products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for … Read more